Sep 09, 2019 / 03:05PM GMT
David Ryan Lewis - Morgan Stanley, Research Division - MD
Okay. So let's get going. We're getting kind of a late start here. My apologies. My name is David Lewis, medical device analyst from Morgan Stanley. It's my pleasure to have with me this morning Haemonetics Corporation as we progress through the morning, and their CEO, Chris Simon.
Questions and Answers:
David Ryan Lewis - Morgan Stanley, Research Division - MDWe're going to jump right into it. And Chris, there is -- I think I may not -- I don't think I've ever see a more rapid transformation of a business for a mid-cap medical device company than we've seen at Haemonetics. Frankly, since you joined, we've seen growth acceleration, really transformative costs. So the question, and we talked about a little bit of this in our CEO call a few months back, but what's next for you in terms of what's the next phase of transformation at Haemonetics?
Christopher Simon - Haemonetics Corporation - CEO, President & Director
Yes. Thanks, David. I appreciate the
Trustpilot
